Literature DB >> 8615178

Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.

J Zoldan1, G Friedberg, A Weizman, E Melamed.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615178

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


× No keyword cloud information.
  5 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 3.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

4.  Is there room for non-dopaminergic treatment in Parkinson disease?

Authors:  Abraham Lieberman; Narayanan Krishnamurthi
Journal:  J Neural Transm (Vienna)       Date:  2012-12-16       Impact factor: 3.575

5.  Psychosis in Parkinson's Disease.

Authors:  Laura Marsh
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.